1 Evidencias -Kantar Health, Campinas, SP, Brazil; 2 Universidade Federal do Paraná, PR, Curitiba, Brazil In contrast to what is expected, incorporation of technology by the government does not guarantee that the population will have access to it, particularly due to the APAC system barrier.
The APAC system does not support innovative treatments, leaving patients to receive obsolete therapies. This creates inequality between patients from the public and private system and goes against the Brazilian Constitution and the Brazilian federal law (Law number 8. 080/1990) , which says that all patients have equal rights to healthcare.
Finally, the APAC system needs to be carefully reviewed in order to provide better treatments to patients and accommodate some of the innovations that are still to come. This analysis shows that even if the regulatory organs responsible for Health Technology Assessment decide for the incorporation of a drug, it does not mean that patients will have access to it.
As an example, erlotinib and gefitinib, which cost more than twice the APAC value, have recently been recommended by CONITEC (the National Committee For Health Technology Incorporation) without any alteration in the APAC value. 3 Advanced NSCLC has been one of the most studied types of cancer and a great variety of new technologies, with significant results, are coming to the market. However, the Brazilian Public Health System still does not provide access to therapies that were launched a decade ago, such as bevacizumab. 4, 5 75% of Brazilians depend on SUS for healthcare treatment. According to the Brazilian Constitution, healthcare is a right of the citizen and a duty of the State (it must be provided).
Historically, the Public System is plagued by lack of medication, overcrowding and underfunding.
Most of the newest technologies approved by Regulatory Chambers are available for patients on the Private Health System. That creates a controversial situation, in which some citizens have access to better treatments while others are relegated to receive older and often less beneficial therapies. 3. 4.
DISCUSSION

5.
ABSTRACT OBJECTIVES: Reimbursement of oncology treatments by the Brazilian Public Health System (SUS) is controlled by the Authorization for High Complexity Procedures (APAC) System. Each line of treatment has an APAC code associated with a specific reimbursement value that should cover all drug expenses for one month. However, with innovation and more expensive drugs that have been launched, these fixed values may not be enough to cover drug expenses. In this context, our objective was to compare costs of recommended treatments with values reimbursed by the APAC system.
METHODS:
We reviewed NCCN (National Comprehensive Cancer Network) guidelines for metastatic Non-small cell lung cancer (mNSCLC) and analyzed recommended chemotherapy regimens. Regimens costs were calculated and compared to the APAC value for mNSCLC, which is equivalent to only $ 1,100 BRL ($ 343.75 USD) per month. We used the maximum sales price for government without taxes. For the drugs that already have generics, calculations were made in two different ways: mean price or the lowest price. The following parameters were used to calculate regimens costs by milligrams approach: age 65, weight 70kg, and body surface 1.70m 2 .
RESULTS:
Ten different regimens are recommended for mNSCLC, two target therapies, four bevacizumab and two pemetrexed-based regimens, and other 3 older regimens. By considering mean costs of drugs whose patents have expired, the APAC value does not cover any regimen. Costs ranged from $ 574 to 14,204 BRL ($ 179.30 to 4,439 USD). With the approach using the cheapest drug in the market, only three regimens are covered by the APAC: cisplatin plus docetaxel ($ 574 BRL or $ 179 USD), carboplatin plus docetaxel ($ 1,002 BRL or $ 313 USD) and carboplatin plus paclitaxel ($ 984 BRL or $ 307 USD). In addition, with the exception of target therapies, all regimens are recommended for 21 days, with two months of APAC corresponding to 3 cycles. Considering this time mismatch, only cisplatin plus docetaxel fits the APAC value.
CONCLUSION: Our analysis indicated that patients might not have access to recommended treatment because the reimbursement system is not updated to the advent of new technologies.
Reimbursement of oncology treatments by the Brazilian Public Health System (SUS) is controlled by the Authorization for High Complexity Procedures (APAC) System. In this system, there is a table of procedures with a corresponding value to each oncologic treatment.
The table of procedures is based on the therapeutic indications and not on chemotherapy, biotherapy or hormone therapy drugs per se.
Although chemotherapy treatment is administered in cycles, the APAC value corresponds to one month of treatment and one APAC code cannot be requested more than once per month.
This means that the total cost of treatment is divided by the number of months that a patient is treated and the result of this division is the amount to be paid each month.
Lung cancer is one of the most incident diseases in Brazil and worldwide. Non-small-cell lung carcinoma (NSCLC) is the most prevalent type of lung cancer and is described as one of the most genomically diverse of all cancers. 
RESULTS
Ten different regimens are recommended for mNSCLC by the NCCN guidelines:
All drugs used are currently available in SUS.
NCCN guidelines
2 target therapies 4 bevacizumab-based regimens 2 pemetrexed-based regimens 3 older regimens (see Table 1 The following parameters were used to calculate regimens costs by milligrams approach: age 65, weight 70kg, and body surface 1,70m 2 . Drug prices were retrieved from the list published by CMED (Câmara de Regulação do Mercado de Medicamentos -Regulatory Chamber of Drug Market).
We analyzed two scenarios, with different estimates, in order to cover a wider range of likely paid prices.
• • "Palliative chemotherapy for NSCLC with stage III malignant pleural effusion, stage IV or recurrent disease and performance status 0 to 1." Scenario 1 -using Factory Price (FP) with 18% of added tax (ICMS -Imposto Sobre Circulação de Mercadorias e Serviços). For the drugs that already had generics, calculations were made in two different ways: lowest price and lowest price with 30% and 50% discounts.
Scenario 2 -Maximum sales price for government (MSPG) with no added tax. For the drugs that already had generics, calculations were made in two different ways: mean price and lowest price.
Note: D=day; mg=milligrams; AUC=area under the curve; m2=meters squared; kg=kilograms Assuming a discount of 30%, which is the average given for generic drugs, two regimens would be covered:
Considering the highest percentage of discount (50%), which is usually the maximum given, three regimens would be reimbursed:
Beside these three older and cheaper regimens, all the others cost more than $ 3,000 BRL, which would make them impossible to be reimbursed.
Also, with the exception of target therapies, all regimens should be administered every 21 days. So two months of APAC would have to cover for 3 treatment cycles. Considering this time mismatch, only cisplatin + docetaxel would fit the APAC value and even so, only with discounted prices (30% and 50%). The carboplatin + docetaxel regimen cost only $ 20 BRL over the APAC value, therefore, this regimen may fit by getting more discounts or due to variations in patients characteristics.
Cisplatin + docetaxel, carboplatin + paclitaxel and carboplatin + docetaxel.
All costs (MSPG) without added taxes are showed in Figure 2 . For these calculations, we assumed the conservative approach of one cycle per month.
•
Scenario 2
By considering mean costs of drugs whose patents have expired, the APAC value does not cover any of the regimens.
Costs ranged from $ 2,205 to 14,205 BRL ($ 4,439 to 689,06 USD).
Considering the lowest costs of drugs in the market, only three regimens would be covered by the APAC value: 
APAC value Lowest Cost generic drug
Mean cost generic drugs
